Dr Richard R. Furman, M.D.
Director of the CLL Research Center
Member of the Lymphoma/Myeloma Service
Division of Hematology/Oncology
Weill Cornell Medicine, New York

“Update in the treatment of Chronic Lymphocytic leukemia”

Wednesday, January 18, 2017
Glen – Cedars Cancer Centre
Room D02.1312
08:30 to 09:30

Hôpital Maisonneuve-Rosemont
Room 0-80 (Pavillon Marcel Lamoureux)
12:00 to 13:00

Hôpital Notre-Dame
Amphithéâtre Deschamps
17:00 to 18:00

Live on the Web! www.vpsolution.tv/vspo
Problems/Questions: 514 813-4510

Thursday, January 19, 2017
Jewish General Hospital
Room E-711
12:30 to 13:30

Hôpital du Sacré-Cœur de Montréal
Room G-4130
15:00 to 16:00

Friday, January 20, 2017
Hôpital Charles Le Moyne
Room HN-106
9:00 to 10:00

Learning Objectives
• To discuss the role of novel agents in the management of frontline CLL and how to approach patient selection
• To consider the evolving role of novel agents in the management of relapsed CLL and how to sequence therapies
• To share experience and best practices of effective management of adverse events associated with novel agents for CLL

Visioconference Request: vspo@mcgill.ca

This event is approved for up to 1 credit by the Office for Continuing Professional Development. The Office for CPD, Faculty of Medicine, McGill University is fully accredited by the Committee on Accreditation of Canadian Medical Education (CACME). This event is an Accredited Group Learning Activity as defined by the Maintenance of Certification program of the Royal College of Physicians and Surgeons of Canada. Through an agreement between the Royal College of Physicians and Surgeons of Canada and the American Medical Association, physicians may convert Royal College MOC credits to AMA PRA Category 1 Credits™. Information on the process to convert Royal College MOC credit to AMA credit can be found at www.amaassn.org/go/internationalcme. Each physician should claim only credit commensurate with the extent of their participation in the activity. For more information, please visit our website at: http://www.medicine.mcgill.ca/oncology/speakers/speakers_visitingspeakers.asp

This program has received an educational grant from:
AbbVie, Alexion, Amgen, Astellas, AstraZeneca, Bayer, Boehringer Ingelheim, Bristol-Myers Squibb, Celgene, Eisai, Eli Lilly, Gilead, Janssen, Lundbeck, Merck, Novartis, Pfizer, Roche, Seattle Genetics